HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

PURPOSE: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast canc...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Clin Cancer Res
المؤلفون الرئيسيون: Xu, Xiaowei, De Angelis, Carmine, Burke, Kathleen A., Nardone, Agostina, Hu, Huizhong, Qin, Lanfang, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Heiser, Laura M., Wang, Nicholas, Ng, Charlotte K.Y., Chen, Edward S., Renwick, Alexander, Wang, Tao, Nanda, Sarmistha, Shea, Martin, Mitchell, Tamika, Rajendran, Mahitha, Waters, Ian, Zabransky, Daniel J., Scott, Kenneth L., Gutierrez, Carolina, Nagi, Chandandeep, Geyer, Felipe C., Chamness, Gary C., Park, Ben H., Shaw, Chad A., Hilsenbeck, Susan G., Rimawi, Mothaffar F., Gray, Joe W., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
التنسيق: Artigo
اللغة:Inglês
منشور في: 2017
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762201/
https://ncbi.nlm.nih.gov/pubmed/28487443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2191
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة